Hexamine and Sodium Acid Phosphate Tablets

Land: Storbritannia

Språk: engelsk

Kilde: VMD (Veterinary Medicines Directorate)

Aktiv ingrediens:

Hexamine, Sodium Dihydrogen Phosphate Anhydrous

Tilgjengelig fra:

Dechra Limited

ATC-kode:

amended)

INN (International Name):

Hexamine, Sodium Dihydrogen Phosphate Anhydrous

Autorisasjon status:

Expired

Preparatomtale

Revised: February 2010
(ATCVet code amended)
SUMMARY OF PRODUCT CHARACTERISTICS
1.
NAME OF THE VETERINARY MEDICINAL PRODUCT
Hexamine and Sodium Acid Phosphate Tablets
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
ACTIVE SUBSTANCES
Qualitative composition
Hexamine
Sodium Acid Phosphate Anhydrous
(equivalent to NaH
2
PO
4
.2H
2
0, 150
mg/tablet)
EXCIPIENTS
For a full list of excipients, see
section 6.1.
Quantitative composition
150 mg/tablet
116 mg/tablet
3.
PHARMACEUTICAL FORM
Tablets.
White, biconvex tablets, 9.5 mm in diameter.
4.
CLINICAL PARTICULARS
4.1
TARGET SPECIES
Dogs.
4.2
INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES
As an antiseptic and urinary acidifier combination to aid in the
control of
cystitis infections of the urinary tract in dogs.
4.3
CONTRAINDICATIONS
None.
4.4
SPECIAL WARNINGS FOR EACH TARGET SPECIES
None.
Revised: February 2010
(ATCVet code amended)
4.5
SPECIAL PRECAUTIONS FOR USE
i.
Special precautions for use in animals
None.
ii.
Special precautions for the person administering the veterinary
medicinal
product to animals
Wash hands thoroughly after handling tablets. Wear protective rubber
gloves
if there is a known hypersensitivity to this product.
Accidental eye contact: rinse thoroughly with clean water and seek
medical
advice.
Accidental ingestion: drink plenty of water and seek medical
attention.
ADVICE TO DOCTOR: Hexamine is metabolised to formaldehyde; an
alkalinising agent such as sodium bicarbonate or large quantities of
water
are recommended.
4.6
ADVERSE REACTIONS (FREQUENCY AND SERIOUSNESS)
None known.
4.7
USE DURING PREGNANCY, LACTATION OR LAY
No special precautions.
4.8
INTERACTION WITH OTHER MEDICINAL PRODUCTS AND OTHER FORMS OF
INTERACTION
None known.
4.9
AMOUNT(S) TO BE ADMINISTERED AND ADMINISTRATION ROUTE
Dogs: 1 - 2 tablets daily.
For oral administration.
This product is suitable for sustained therapy over a long period, but
for the
initial period of therapy consult your veterinary surgeon.
4.10
OVERDOSE (SYMPTOMS, EMERGENCY PROCEDURES, ANTIDOTES), IF NECESSARY
None re